Industry News (Joint Venture)

Agreement Signed for Cancer Collaboration

Published in Cancer Weekly, October 6th, 1997

Cel-Sci Corp., Alexandria, Virginia, announced that it has signed a letter of intent to enter into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI) to jointly test the L.E.A.P.S. (Ligand Epitope Antigen Presentation System) heteroconjugate technology in NCI animal models for prostate and breast cancers. The work has been projected to start before the end of 1997.

The goal of these studies is to develop an effective immunotherapeutic response against prostate and breast cancers. Cel-Sci's L.E.A.P.S. technology has been scheduled for testing with the SV40 T-antigen peptides using the C3(1)/Tag transgenic mouse model...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-10-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry